Patient Centricity, Awareness, and Direct Outreach
Alpha Omega has developed and utilizes an effective system of direct-to-consumer (DTC) outreach with the goal of maximizing the volume of relevant information being imparted to the potential participants about various aspects of clinical trials for reasons related to patient literacy, which in turn minimizes the chances of such participants prematurely dropping out of clinical trials, thus increasing the patient retention rates.
Alpha Omega’s DTC outreach program is also highly effective in terms of advertising and raising awareness about various clinical trials, attracting the attention of potential participants and physicians alike.
DTC outreach: We assist Investigators in increasing the awareness among potential participants of clinical trials by organizing seminars for participants and their families to familiarize them with the clinical trial process and educating them on how such research contributes to the development of new treatments. We additionally assist Investigators in the business of digital marketing, website, social media, explainer videos, and mobile applications, which are all critical tools in ensuring that both clinicians and patients become aware of relevant studies.
Patient-centric Approach: Alpha Omega is also mindful of how logistical and financial issues on the part of the potential participant, specifically the issues related to access and transportation, may impact patient recruitment and retention rates.
Accordingly, Cromos Pharma has developed and implemented appropriate reimbursement plans to ensure that we can tap into the pool of potential subjects who would otherwise not be able to participate in clinical trials due to financial or logistical reasons.
Commitment to patients: We have created robust reimbursement procedures (taxi, accommodations, meal vouchers) for enrolled patients.
Protecting health and safety of trial participants is extremely important to us at Cromos Pharma. We exercise extreme diligence in our approach to site selection and to choosing Investigators. While most companies face challenges in subject recruitment and retention, Cromos Pharma is consistently on track when it comes to achieving the “Last Patient In” target. Our key focus is on maintaining our extensive professional network, which has consistently delivered patients supportive of the clinical trial research process.
By analyzing study population, sites’ motivation to enroll, type of disease, and subjects’ barriers to participation (e.g., travel distances, number of visits, etc.), we have developed a proprietary algorithm that facilitates identification, recruitment, and retention of the precise type of patients needed for the successful trial conduct.
Finally, Alpha Omega engages itsfeasibility team during the startup phase of each trial. By doing this, the knowledge gained during the feasibility process is shared and transferred efficiently to the clinical operations team. This ensures effective launch and subsequent conduct of every clinical program.